$472.35
0.68% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US45168D1046
Symbol
IDXX
Sector

IDEXX Laboratories Stock price

$472.35
+2.98 0.63% 1M
-85.11 15.27% 6M
-82.70 14.90% YTD
-15.61 3.20% 1Y
-215.98 31.38% 3Y
+183.88 63.74% 5Y
+409.89 656.18% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+3.17 0.68%
ISIN
US45168D1046
Symbol
IDXX
Sector

Key metrics

Market capitalization $38.88b
Enterprise Value $39.54b
P/E (TTM) P/E ratio 46.82
EV/FCF (TTM) EV/FCF 47.13
EV/Sales (TTM) EV/Sales 10.45
P/S ratio (TTM) P/S ratio 10.27
P/B ratio (TTM) P/B ratio 24.65
Revenue growth (TTM) Revenue growth 7.70%
Revenue (TTM) Revenue $3.78b
EBIT (operating result TTM) EBIT $1.08b
Free Cash Flow (TTM) Free Cash Flow $838.95m
Cash position $401.59m
EPS (TTM) EPS $10.09
P/E forward 44.98
P/S forward 9.93
EV/Sales forward 10.10
Short interest 3.76%
Show more

Create a Free Account to create an IDEXX Laboratories alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

IDEXX Laboratories Stock Analysis

Analyst Opinions

12 Analysts have issued a IDEXX Laboratories forecast:

6x Buy
50%
5x Hold
42%
1x Sell
8%

Analyst Opinions

12 Analysts have issued a IDEXX Laboratories forecast:

Buy
50%
Hold
42%
Sell
8%

Financial data from IDEXX Laboratories

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
3,785 3,785
8% 8%
100%
- Direct Costs 1,499 1,499
5% 5%
40%
2,286 2,286
9% 9%
60%
- Selling and Administrative Expenses 874 874
15% 15%
23%
- Research and Development Expense 208 208
14% 14%
5%
1,204 1,204
5% 5%
32%
- Depreciation and Amortization 121 121
6% 6%
3%
EBIT (Operating Income) EBIT 1,083 1,083
5% 5%
29%
Net Profit 846 846
7% 7%
22%

In millions USD.

Don't miss a Thing! We will send you all news about IDEXX Laboratories directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEXX Laboratories Stock News

Neutral
Business Wire
17 days ago
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Jay Mazelsky, President and Chief Executive Officer, and Brian McKeon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 202...
Neutral
Seeking Alpha
27 days ago
IDEXX reported lower full-year organic revenue growth due to reduced U.S. clinical visits. Weak consumer sentiment and ongoing staffing challenges may continue to impact clinical visits in the near future. Launch of new menu expansion for Catalyst platform may drive growth in diagnostic business, but the stock remains overvalued.
Neutral
Seeking Alpha
about one month ago
IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participants Chris Schott - JPMorgan Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jonathan Block - Stifel David Westenberg - Piper Sandler Operator Good morning, and welcome to the IDEXX Labor...
More IDEXX Laboratories News

Company Profile

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management. The Water segment develops, designs, manufactures, and distributes a range of products used in the detection of various microbiological parameters in water. The LPD segment develops, designs, manufactures, and distributes diagnostic tests and related instrumentation and performs services, which are used to manage the health status of livestock and poultry, to improve producer, and to ensure the quality and safety of milk and food. The Other operating segment combines and presents products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

Head office United States
CEO Jonathan Mazelsky
Employees 11,000
Founded 1983
Website www.idexx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today